Apalutamide-induced ichthyosiform eruption
https://doi.org/10.4081/dr.2023.9734
HTML: 20
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Dear Editor, Skin eruptions are commonly observed in patients undergoing anticancer therapy, and with the introduction of new drugs in the antitumor treatment landscape evidence regarding their potential cutaneous adverse effects is still building. We herein report the case of an acquired ichthyosiform reaction induced by apalutamide. [...]
Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-503.
Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381:13-24.
Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79:150-8.
Uemura H, Koroki Y, Iwaki Y, et al. Skin rash following administration of apalutamide in Japanese patients with advanced prostate cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study. BMC Urol 2020;20:139.
Miyagawa F, Akioka N, Yoshida N, et al. Psoriatic skin lesions after apalutamide treatment. Acta Derm Venereol 2022;102:adv00659.
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
